안구건조증 치료 시장 규모, 점유율, 동향 분석 리포트 : 유형별, 약제별, 제품별, 제형별, 판매채널별, 유통 채널별, 지역별, 부문 예측(2025-2030년)

Dry Eye Syndrome Treatment Market Growth & Trends:

The global dry eye syndrome treatment market size is estimated to reach USD 9.20 billion by 2030, expanding at a CAGR of 6.5% from 2025 to 2030, according to a new report by Grand View Research, Inc. The growth of the market is attributed to factors such as the increasing use of screens, the rising geriatric population, and a heightened prevalence of eye diseases.

The heightened use of devices with a screen, surging use of computers, and a decreased number of blinks are subsequently leading to the growth of evaporative dry eye syndrome globally. For instance, as per Frontiers Journal in 2021, when compared to pre-pandemic years, the use of screens has increased by 60-80% in adults during the COVID-19 pandemic. The exposure to the screen leads to a 66% decreased blinking rate, thus escalating the evaporation of tears and leading to dry eye disease.

Over-the-counter (OTC) products predominate the marketplace due to the extremely low acceptance of prescription products. For instance, only 10% of the diagnosed population is on prescription therapies, while 75% of the population has never tried prescription therapy. However, the number of patients diagnosed with dry eye syndrome accounts for 5-35% of overall ophthalmologist visits.

Moreover, existing products such as Xiidra and Restasis take months or weeks to demonstrate effects. In addition, as per eye consultants, these products have tolerability issues and a failure rate of as high as 50%. This depicts an unmet need in the market and is anticipated to create a lucrative opportunity for pipeline products expected to launch in the upcoming years. Moreover, regulations associated with the drugs further hamper the growth of the overall market. For instance, in 2020, Novartis had to voluntarily withdraw the use of Xiidra in Europe after regulators raised major objections to its use of xiidra.

Innovations and strategic initiatives by key players are driving the market. New product launch is a common strategy being used by the players. For instance, in October 2021, Tyrvaya (varenicline solution) nasal spray by Oyster Point Pharma was approved by the FDA as an alternative treatment approach.

Dry Eye Syndrome Treatment Market Report Highlights:

• By type, Evaporative dry eye syndrome segment dominated the market with the largest market share in 2024 and is also anticipated to grow with the fastest CAGR during the forecast period
• Based on dosage form, The eye drops/ solutions segment dominated the market with the largest share of 64.68% in 2024
• By drug, The Xiidra segment dominated the overall market in 2024, with a revenue share of 8.52%.
• Based on distribution channel, online pharmacies are expected to grow at the fastest rate over the forecast period due to the increased consumer preference for online pharmacies owing to the convenience
• North America dominated the market in 2023 due to the high prevalence of the disease, surging awareness, and enhanced treatment rate

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation and Scope
• 1.2. Segment Definitions
  • 1.2.1. Type
  • 1.2.2. Drugs
  • 1.2.3. Product
  • 1.2.4. Dosage Form
  • 1.2.5. Sales Channel
  • 1.2.6. Distribution Channel
  • 1.2.7. Regional Scope
  • 1.2.8. Estimates and forecasts timeline
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
  • 1.4.5. Details of primary research
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis (Model 1)
  • 1.7.2. Approach 1: Commodity flow approach
  • 1.7.3. Volume price analysis (Model 2)
  • 1.7.4. Approach 2: Volume price analysis
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Type outlook
  • 2.2.2. Drugs outlook
  • 2.2.3. Product outlook
  • 2.2.4. Dosage form outlook
  • 2.2.5. Sales channel outlook
  • 2.2.6. Distribution channel outlook
• 2.3. Regional outlook
• 2.4. Competitive Insights

Chapter 3. Dry Eye Syndrome Treatment Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market Outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
    • 3.2.1.1. Growing geriatric population
    • 3.2.1.2. Increasing prevalence of dry eye syndrome
    • 3.2.1.3. Robust product pipeline
    • 3.2.1.4. Growing disease awareness and increasing use of contact lenses
  • 3.2.2. Market Restraint Analysis
    • 3.2.2.1. Competition from generic products
    • 3.2.2.2. High cost of treatments and lack of awareness among the general population in low- and middle-income countries
• 3.3. Dry Eye Syndrome Treatment Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
    • 3.3.1.1. Bargaining power of suppliers
    • 3.3.1.2. Bargaining power of buyers
    • 3.3.1.3. Threat of substitutes
    • 3.3.1.4. Threat of new entrants
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Economic landscape
    • 3.3.2.3. Social landscape
    • 3.3.2.4. Technological landscape
    • 3.3.2.5. Environmental landscape
    • 3.3.2.6. Legal landscape

Chapter 4. Dry Eye Syndrome Treatment Market: Type Estimates & Trend Analysis

• 4.1. Segment Dashboard
• 4.2. Dry Eye Syndrome Treatment Market: Type Movement Analysis
• 4.3. Dry Eye Syndrome Treatment Market by Type Outlook (USD Million)
• 4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
• 4.5. Evaporative Dry Eye Syndrome
  • 4.5.1. Market Estimates And Forecast, 2018 - 2030 (USD Million)
• 4.6. Aqueous Deficient Dry Eye Syndrome
  • 4.6.1. Market Estimates And Forecast, 2018 - 2030 (USD Million)

Chapter 5. Dry Eye Syndrome Treatment Market: Drugs Estimates & Trend Analysis

• 5.1. Segment Dashboard
• 5.2. Dry Eye Syndrome Treatment Market: Drugs Movement Analysis
• 5.3. Dry Eye Syndrome Treatment Market by Drugs Outlook (USD Million)
• 5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
• 5.5. Xiidra
  • 5.5.1. Market Estimates And Forecast, 2018 - 2030 (USD Million)
• 5.6. Restasis
  • 5.6.1. Market Estimates And Forecast, 2018 - 2030 (USD Million)
• 5.7. Cequa
  • 5.7.1. Market Estimates And Forecast, 2018 - 2030 (USD Million)
• 5.8. Tyrvaya
  • 5.8.1. Market Estimates And Forecast, 2018 - 2030 (USD Million)
• 5.9. Eysuvis
  • 5.9.1. Market Estimates And Forecast, 2018 - 2030 (USD Million)
• 5.10. Others
  • 5.10.1. Market Estimates And Forecast, 2018 - 2030 (USD Million)

Chapter 6. Dry Eye Syndrome Treatment Market: Product Estimates & Trend Analysis

• 6.1. Segment Dashboard
• 6.2. Dry Eye Syndrome Treatment Market: Product Movement Analysis
• 6.3. Dry Eye Syndrome Treatment Market by Product Outlook (USD Million)
• 6.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
• 6.5. Artificial Tears
  • 6.5.1. Market Estimates And Forecast, 2018 - 2030 (USD Million)
• 6.6. Cyclosporine
  • 6.6.1. Market Estimates And Forecast, 2018 - 2030 (USD Million)
• 6.7. Topical Corticosteroids
  • 6.7.1. Market Estimates And Forecast, 2018 - 2030 (USD Million)
• 6.8. Punctal Plugs
  • 6.8.1. Market Estimates And Forecast, 2018 - 2030 (USD Million)
• 6.9. Oral Omega Supplements
  • 6.9.1. Market Estimates And Forecast, 2018 - 2030 (USD Million)
• 6.10. Others
  • 6.10.1. Market Estimates And Forecast, 2018 - 2030 (USD Million)

Chapter 7. Dry Eye Syndrome Treatment Market: Dosage Form Estimates & Trend Analysis

• 7.1. Segment Dashboard
• 7.2. Dry Eye Syndrome Treatment Market: Dosage Form Movement Analysis
• 7.3. Dry Eye Syndrome Treatment Market by Dosage Form Outlook (USD Million)
• 7.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
• 7.5. Eye Drops/ Solutions
  • 7.5.1. Market Estimates And Forecast, 2018 - 2030 (USD Million)
• 7.6. Ointments and Gels
  • 7.6.1. Market Estimates And Forecast, 2018 - 2030 (USD Million)
• 7.7. Capsules & Tablets (For Supplements)
  • 7.7.1. Market Estimates And Forecast, 2018 - 2030 (USD Million)
• 7.8. Other Dosage Forms
  • 7.8.1. Market Estimates And Forecast, 2018 - 2030 (USD Million)

Chapter 8. Dry Eye Syndrome Treatment Market: Sales Channel Estimates & Trend Analysis

• 8.1. Segment Dashboard
• 8.2. Dry Eye Syndrome Treatment Market: Sales Channel Movement Analysis
• 8.3. Dry Eye Syndrome Treatment Market by Sales Channel Outlook (USD Million)
• 8.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
• 8.5. Prescription
  • 8.5.1. Market Estimates And Forecast, 2018 - 2030 (USD Million)
• 8.6. OTC
  • 8.6.1. Market Estimates And Forecast, 2018 - 2030 (USD Million)
• 8.7. Others
  • 8.7.1. Market Estimates And Forecast, 2018 - 2030 (USD Million)

Chapter 9. Dry Eye Syndrome Treatment Market: Distribution Channel Estimates & Trend Analysis

• 9.1. Segment Dashboard
• 9.2. Dry Eye Syndrome Treatment Market: Distribution Channel Movement Analysis
• 9.3. Dry Eye Syndrome Treatment Market by Distribution Channel Outlook (USD Million)
• 9.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
• 9.5. Retail Pharmacies
  • 9.5.1. Market Estimates And Forecast, 2018 - 2030 (USD Million)
• 9.6. Hospital Pharmacies
  • 9.6.1. Market Estimates And Forecast, 2018 - 2030 (USD Million)
• 9.7. Online Pharmacies
  • 9.7.1. Market Estimates And Forecast, 2018 - 2030 (USD Million)

Chapter 10. Dry Eye Syndrome Treatment Market: Regional Estimates & Trend Analysis

• 10.1. Regional Dashboard
• 10.2. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
• 10.3. North America
  • 10.3.1. U.S.
    • 10.3.1.1. Key country dynamics
    • 10.3.1.2. Regulatory framework/ reimbursement structure
    • 10.3.1.3. Competitive scenario
    • 10.3.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
  • 10.3.2. Canada
    • 10.3.2.1. Key country dynamics
    • 10.3.2.2. Regulatory framework/ reimbursement structure
    • 10.3.2.3. Competitive scenario
    • 10.3.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
  • 10.3.3. Mexico
    • 10.3.3.1. Key country dynamics
    • 10.3.3.2. Regulatory framework/ reimbursement structure
    • 10.3.3.3. Competitive scenario
    • 10.3.3.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
• 10.4. Europe
  • 10.4.1. UK
    • 10.4.1.1. Key country dynamics
    • 10.4.1.2. Regulatory framework/ reimbursement structure
    • 10.4.1.3. Competitive scenario
    • 10.4.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
  • 10.4.2. Germany
    • 10.4.2.1. Key country dynamics
    • 10.4.2.2. Regulatory framework/ reimbursement structure
    • 10.4.2.3. Competitive scenario
    • 10.4.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
  • 10.4.3. France
    • 10.4.3.1. Key country dynamics
    • 10.4.3.2. Regulatory framework/ reimbursement structure
    • 10.4.3.3. Competitive scenario
    • 10.4.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
  • 10.4.4. Italy
    • 10.4.4.1. Key country dynamics
    • 10.4.4.2. Regulatory framework/ reimbursement structure
    • 10.4.4.3. Competitive scenario
    • 10.4.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
  • 10.4.5. Spain
    • 10.4.5.1. Key country dynamics
    • 10.4.5.2. Regulatory framework/ reimbursement structure
    • 10.4.5.3. Competitive scenario
    • 10.4.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
  • 10.4.6. Norway
    • 10.4.6.1. Key country dynamics
    • 10.4.6.2. Regulatory framework/ reimbursement structure
    • 10.4.6.3. Competitive scenario
    • 10.4.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
  • 10.4.7. Sweden
    • 10.4.7.1. Key country dynamics
    • 10.4.7.2. Regulatory framework/ reimbursement structure
    • 10.4.7.3. Competitive scenario
    • 10.4.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
  • 10.4.8. Denmark
    • 10.4.8.1. Key country dynamics
    • 10.4.8.2. Regulatory framework/ reimbursement structure
    • 10.4.8.3. Competitive scenario
    • 10.4.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
• 10.5. Asia Pacific
  • 10.5.1. Japan
    • 10.5.1.1. Key country dynamics
    • 10.5.1.2. Regulatory framework/ reimbursement structure
    • 10.5.1.3. Competitive scenario
    • 10.5.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
  • 10.5.2. China
    • 10.5.2.1. Key country dynamics
    • 10.5.2.2. Regulatory framework/ reimbursement structure
    • 10.5.2.3. Competitive scenario
    • 10.5.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
  • 10.5.3. India
    • 10.5.3.1. Key country dynamics
    • 10.5.3.2. Regulatory framework/ reimbursement structure
    • 10.5.3.3. Competitive scenario
    • 10.5.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
  • 10.5.4. Australia
    • 10.5.4.1. Key country dynamics
    • 10.5.4.2. Regulatory framework/ reimbursement structure
    • 10.5.4.3. Competitive scenario
    • 10.5.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
  • 10.5.5. South Korea
    • 10.5.5.1. Key country dynamics
    • 10.5.5.2. Regulatory framework/ reimbursement structure
    • 10.5.5.3. Competitive scenario
    • 10.5.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
  • 10.5.6. Thailand
    • 10.5.6.1. Key country dynamics
    • 10.5.6.2. Regulatory framework/ reimbursement structure
    • 10.5.6.3. Competitive scenario
    • 10.5.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
• 10.6. Latin America
  • 10.6.1. Brazil
    • 10.6.1.1. Key country dynamics
    • 10.6.1.2. Regulatory framework/ reimbursement structure
    • 10.6.1.3. Competitive scenario
    • 10.6.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
  • 10.6.2. Argentina
    • 10.6.2.1. Key country dynamics
    • 10.6.2.2. Regulatory framework/ reimbursement structure
    • 10.6.2.3. Competitive scenario
    • 10.6.2.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
• 10.7. MEA
  • 10.7.1. South Africa
    • 10.7.1.1. Key country dynamics
    • 10.7.1.2. Regulatory framework/ reimbursement structure
    • 10.7.1.3. Competitive scenario
    • 10.7.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
  • 10.7.2. Saudi Arabia
    • 10.7.2.1. Key country dynamics
    • 10.7.2.2. Regulatory framework/ reimbursement structure
    • 10.7.2.3. Competitive scenario
    • 10.7.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
  • 10.7.3. UAE
    • 10.7.3.1. Key country dynamics
    • 10.7.3.2. Regulatory framework/ reimbursement structure
    • 10.7.3.3. Competitive scenario
    • 10.7.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
  • 10.7.4. Kuwait
    • 10.7.4.1. Key country dynamics
    • 10.7.4.2. Regulatory framework/ reimbursement structure
    • 10.7.4.3. Competitive scenario
    • 10.7.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 11. Competitive Landscape

• 11.1. Company Categorization
• 11.2. Recent Developments & Impact Analysis by Key Market Participants
• 11.3. Company Market Share Analysis, 2024
• 11.4. Company overview
  • 11.4.1. Novartis AG
    • 11.4.1.1. Company Overview
    • 11.4.1.2. Financial performance
    • 11.4.1.3. Product benchmarking
    • 11.4.1.4. Strategic initiatives
  • 11.4.2. AbbVie, Inc.
    • 11.4.2.1. Company Overview
    • 11.4.2.2. Financial performance
    • 11.4.2.3. Product benchmarking
    • 11.4.2.4. Strategic initiatives
  • 11.4.3. Sun Pharmaceutical Industries Ltd.
    • 11.4.3.1. Company Overview
    • 11.4.3.2. Financial performance
    • 11.4.3.3. Product benchmarking
    • 11.4.3.4. Strategic initiatives
  • 11.4.4. Santen Pharmaceutical Co Ltd.
    • 11.4.4.1. Company Overview
    • 11.4.4.2. Financial performance
    • 11.4.4.3. Product benchmarking
    • 11.4.4.4. Strategic initiatives
  • 11.4.5. AFT Pharmaceuticals
    • 11.4.5.1. Company Overview
    • 11.4.5.2. Financial performance
    • 11.4.5.3. Product benchmarking
    • 11.4.5.4. Strategic initiatives
  • 11.4.6. Johnson & Johnson Services, Inc.
    • 11.4.6.1. Company Overview
    • 11.4.6.2. Financial performance
    • 11.4.6.3. Product benchmarking
    • 11.4.6.4. Strategic initiatives
  • 11.4.7. Otsuka Pharmaceutical Co., Ltd. (subsidiary of Otsuka Holdings Co., Ltd.)
    • 11.4.7.1. Company Overview
    • 11.4.7.2. Financial performance
    • 11.4.7.3. Product benchmarking
    • 11.4.7.4. Strategic initiatives
  • 11.4.8. OASIS Medical
    • 11.4.8.1. Company Overview
    • 11.4.8.2. Financial performance
    • 11.4.8.3. Product benchmarking
    • 11.4.8.4. Strategic initiatives
  • 11.4.9. Oyster Point Pharma, Inc. (acquired by Viatris Inc. in January 2023)
    • 11.4.9.1. Company Overview
    • 11.4.9.2. Financial performance
    • 11.4.9.3. Product benchmarking
    • 11.4.9.4. Strategic initiatives
  • 11.4.10. Bausch Health Companies, Inc.
    • 11.4.10.1. Company Overview
    • 11.4.10.2. Financial performance
    • 11.4.10.3. Product benchmarking
    • 11.4.10.4. Strategic initiatives